We are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, currently focused on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.
Poxel's innovative pipeline of first-in-class products with disease-modifying mechanisms of action offers the potential for safer and more effective therapies for type 2 diabetes. Our lead compound, Imeglimin, has successfully completed Phase 2 clinical development for type 2 diabetes in the U.S. and EU. The Phase 3 TIMES program is currently underway in Japan.
Inception date: 2009
Stock market: Euronext Paris - Compartment B
ISIN code: FR0012432516
First day of trading: February 6, 2015 (on Euronext)
Number of Shares Outstanding: 24,558,827